This is a high-risk, binary event for a micro-cap company pivoting from beverages to biopharma. Monitor for any FDA clinical trial updates, partnership announcements, or capital raises. The $1M investment is insufficient for a full US clinical program — watch for dilutive financing needs. The stock may trade on sentiment around CannEpil's existing European revenue, but no revenue figures were disclosed.
Price Chart
Executive Summary
Splash Beverage Group (SBEV) announced an exclusive global licensing agreement for CannEpil, a cannabinoid-based epilepsy therapy, from Argent BioPharma (RGT). The deal includes a $1M strategic investment from C/M Capital Partners, forgiveness of ~$5M of Argent's debt by Mercer Street Global Opportunity Fund, and issuance of $5.5M in SBEV preferred equity. While the asset has existing European patient access and FDA pre-IND engagement, SBEV has a $2M market cap and no disclosed revenue from the license, making the transaction highly speculative.
Key Facts
- SBEV acquired exclusive global rights to CannEpil, a cannabinoid-based therapy for drug-resistant epilepsy
- CannEpil has been prescribed in Ireland, UK, Germany, and Australia under regulated access programs
- CannEpil has an FDA IND number and pre-IND engagement initiated
- C/M Capital Partners committed a $1M strategic investment to support development
- Mercer Street Global Opportunity Fund forgave ~$5M of Argent BioPharma's debt as part of the consideration
- SBEV issued $5.5M of newly issued preferred equity as part of the license consideration
- Argent BioPharma will receive a 15% royalty on net revenue from worldwide CannEpil sales
- The license has a 20-year initial term with sublicensing rights
- SBEV market cap is $2M; no revenue or financial projections from the license were disclosed
Financial Impact
SBEV issued $5.5M in preferred equity and secured a $1M investment commitment; ~$5M of Argent debt was forgiven. No revenue or profitability guidance provided.
Risk Factors
- SBEV has a $2M market cap and no disclosed revenue from the license — highly speculative
- CannEpil requires FDA approval for US commercialization, which is uncertain and costly
- SBEV will need significant additional capital for US clinical trials, likely causing dilution
- The company is pivoting from beverages to biopharma — no track record in drug development
- 15% royalty to Argent reduces net revenue from any future sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-000910 |
| Document: e7759_ex99-1.htm | 0001731122-26-000910 |
| Document: 0001731122-26-000910-index-headers.html | 0001731122-26-000910 |
| Document: 0001731122-26-000910-index.html | 0001731122-26-000910 |
| Document: 0001731122-26-000910.txt | 0001731122-26-000910 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 19d ago | DEFA14A | — | awaiting T+5 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.4715 | awaiting T+5 | — | — |
Aug 21, 2026 9w ago | 8-K | $0.4376 | awaiting T+5 | — | — |
Aug 20, 2026 9w ago | 8-K | $0.4250 | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $0.4096 $0.4104 | ▲ +0.20% | ▲ +0.64% | — |
Aug 7, 2026 11w ago | S-1 | $0.4122 $0.3780 | ▲ +8.30% | ▲ +8.25% | — |
Aug 5, 2026 11w ago | 8-K | $0.4250 $0.4096 | ▼ −3.62% | ▼ −3.97% | — |
Jul 14, 2026 14w ago | 8-K | $0.1043 $0.0936 | ▼ −10.26% | ▼ −9.79% | — |
Jul 9, 2026 15w ago | 8-K | $0.1653 $0.0936 | ▲ +43.38% | ▲ +43.24% | — |
Jul 6, 2026 16w ago | 8-K | $0.2081 $0.1240 | ▼ −40.41% | ▼ −40.13% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers